Description
Nm1f is an experimental medication currently being studied in clinical trials for advanced solid tumors, including colorectal cancer. It is being tested in Phase 1 trials to determine its safety, how the body processes it (pharmacokinetics), its effects on the body (pharmacodynamics), and if it shows early signs of fighting cancer. These trials are called 'first-in-human' studies, meaning it's one of the first times the drug is being given to people. Nm1f is being investigated both on its own (monotherapy) and in combination with another immunotherapy drug called pembrolizumab (Keytruda®). The goal of these early trials is to find the right dose and understand how patients respond before moving to larger studies.
Mechanism of Action
Nm1f is being developed as an immunotherapy drug. It targets a specific protein on immune cells called PVRIG (PVRIG). By targeting PVRIG, Nm1f aims to enhance the activity of the immune system, specifically T cells, to help them recognize and attack cancer cells more effectively. PVRIG is thought to act as a 'brake' on the immune response against tumors. Blocking this brake could potentially unleash the immune system to fight the cancer. The specific mechanism and how it interacts with the immune system are being further characterized in ongoing clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.